start the movement —
a progressive Oa staging tool
Canine osteoarthritis (OA) often goes unnoticed. Subtle changes in your patients’ behavior can be warning signs for OA. COAST can help you recognize and treat canine OA from its earliest diagnosed stages to keep your patients comfortable and active throughout their lives.
Leading orthopedic health and pain management experts developed this new staging tool as a standardized approach to diagnose and monitor dogs with clinical signs of OA as well as those at risk of developing OA.1
Use the COAST interactive PDF or downloadable form to make canine OA staging part of your wellness visit routine in a matter of minutes.1
coast info logo
Grade the Dog
One left
Have the dog owner complete a
validated questionnaire and report the
dog’s overall level of discomfort.
One right
Assess the dog’s posture while
stationary and while in motion.
Grade the Joint
Two Image
Determine how much pain there is on manipulation, assess
range of movement and take radiographs.
Select the Highest Grade
from All Evaluations
The highest grade from evaluating the dog or the joint equates to that patient’s COAST stage.*
*If there is a disparity of two or more grades between dog and joint results, re-evaluate.
Discover the importance of the early diagnosis and treatment of canine OA.


Galliprant is an NSAID indicated for the control of pain and inflammation associated with osteoarthritis in dogs.

Important Safety Information

Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. Click here for full prescribing information.